Market closed
iCAD/$ICAD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About iCAD
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Ticker
$ICAD
Sector
Trading on
Industry
Health Care Technology
Headquarters
Employees
68
Website
iCAD Metrics
BasicAdvanced
$52M
Market cap
-
P/E ratio
-$0.10
EPS
1.48
Beta
-
Dividend rate
Price and volume
Market cap
$52M
Beta
1.48
52-week high
$2.65
52-week low
$1.18
Average daily volume
348K
Financial strength
Current ratio
4.019
Quick ratio
3.727
Long term debt to equity
0.65
Total debt to equity
1.413
Interest coverage (TTM)
-437.14%
Management effectiveness
Return on assets (TTM)
-8.95%
Return on equity (TTM)
-17.56%
Valuation
Price to revenue (TTM)
2.741
Price to book
1.77
Price to tangible book (TTM)
2.48
Price to free cash flow (TTM)
-10.556
Growth
Revenue change (TTM)
10.03%
Earnings per share change (TTM)
-73.95%
3-year revenue growth (CAGR)
-19.48%
3-year earnings per share growth (CAGR)
-34.51%
What the Analysts think about iCAD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for iCAD stock.
iCAD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
iCAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
iCAD News
AllArticlesVideos
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
GlobeNewsWire·3 days ago
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
GlobeNewsWire·1 week ago
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for iCAD stock?
iCAD (ICAD) has a market cap of $52M as of December 14, 2024.
What is the P/E ratio for iCAD stock?
The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of December 14, 2024.
Does iCAD stock pay dividends?
No, iCAD (ICAD) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next iCAD dividend payment date?
iCAD (ICAD) stock does not pay dividends to its shareholders.
What is the beta indicator for iCAD?
iCAD (ICAD) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.